NextFin News - Novartis reported on Sunday that its experimental actinium-based radioligand therapy has demonstrated significant anti-tumor activity in patients with advanced prostate cancer, including those who had already failed treatment with the company’s existing blockbuster drug, Pluvicto. Data from a 101-patient early-stage study, presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, revealed that 52.5% of patients previously treated with Pluvicto experienced at least a 50% reduction in prostate-specific antigen (PSA) levels. For patients who had not received prior radioligand therapy, the response rates were even more pronounced, with over 85% of treatment-naive patients reaching the same PSA reduction threshold.
The results underscore the potential of alpha-emitting isotopes like actinium-225 to overcome resistance to current beta-emitting treatments. While Pluvicto utilizes lutetium-177 to deliver radiation, the new experimental drug employs actinium-225, which delivers higher energy over a shorter distance. Shreeram Aradhye, Chief Medical Officer at Novartis, noted that this mechanism allows for potentially greater efficacy by causing more localized and lethal damage to cancer cells. The Swiss pharmaceutical giant is now moving forward with two late-stage studies to further validate these findings, reflecting a strategic pivot where radioligand therapies now command nearly 40% of the company’s oncology research and development budget.
Analysts at TD Cowen, who have maintained a generally constructive view on the radiopharmaceutical sector, observed that while the early data suggest clear efficacy, the drug’s safety profile remains a critical hurdle. The study highlighted high rates of dry mouth and severe anemia among participants. Aradhye acknowledged that larger trials are essential to determine the reversibility and long-term severity of these side effects, particularly as Novartis aims to move the therapy into earlier lines of treatment where the tolerance for toxicity is lower. This cautious optimism from analysts suggests that while the drug is a potent addition to the pipeline, it does not yet represent a guaranteed successor to the current standard of care.
The commercial viability of actinium-based drugs also faces significant logistical headwinds. Industry experts have frequently cited the scarcity of actinium-225 as a bottleneck for the entire radiopharma sector. Novartis has attempted to mitigate this risk by securing a long-term supply agreement with U.S.-based producer Niowave earlier this year. However, the broader market remains skeptical about whether production can scale fast enough to meet global demand if the drug receives regulatory approval. This supply-side constraint is a primary reason why some institutional investors view the rapid expansion of the radiopharma field with a degree of caution, despite the aggressive acquisition activity seen from competitors like Eli Lilly and AstraZeneca.
Novartis is currently the dominant player in this niche, with Pluvicto and Lutathera generating a combined $2.8 billion in revenue last year. The success of this experimental actinium drug is pivotal for the company to maintain its lead as the market for radiopharmaceuticals becomes increasingly crowded. The ability to treat patients who have exhausted other options provides a clear clinical niche, but the transition from a successful early-stage trial to a commercially scalable product will depend entirely on managing the delicate balance between the drug’s high-energy potency and its systemic toxicity. For now, the ASCO data provides a necessary proof of concept for the next generation of nuclear medicine.
Explore more exclusive insights at nextfin.ai.
